BioSpace News Archive

Proceeds to Support Expansion of Commercial Infrastructure Driving Decentralization of Comprehensive Genomic Profiling for Cancer PGDx’s elio™ Platform and Bioinformatics Solution Enable Hospitals and Labs to Deliver World-Class, Actionable Genomic Information to Physicians and Their Patients

BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors

OncoNano Medicine, Inc. today announced that a research paper titled “Prolonged activation of innate immune pathways by a polyvalent STING agonist” published in Nature Biomedical Engineering shows that a pH-sensitive nanoparticle-based drug developed by Dr. Jinming Gao and team at the University of Texas Southwestern Medical Center (UTSW

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. Our focus is on building shareholder value by pursuing pre-market approval for SkinTE® from the U.S. Food and Drug Administration (FDA) through submission of an investigational new drug application (IND) and eventual biologics license application (BLA),

Chill N Out Cryotherapy, Inc. (OTC PINK:CHNO) a Delaware Corporation, which recently had a change in control and completed the acquisition of ClassWorx, Inc. has brought its year end financials for 2018, 2019, and 2020 current along with OTC Pink Guidelines reporting for the same years.

Elekta announced today that the United States Department of Veterans Affairs (VA) National Radiation Oncology Program is poised to pair its major radiotherapy quality program with Elekta’s (EKTA-B.ST)

Formerly Trask Orthodontics, Dr. Sepi Torkan continues the tradition of expert orthodontic care on Sand Point Way in the Laurelhurst neighborhood of Seattle.

SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered an agreement with Procaps

Distinction Punctuates Neurological Spine Surgeon’s Storied Career as a Pioneer in High-Acuity, Minimally Invasive Surgery

Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116.